Platelet Glycolytic Metabolism Correlates with Hemodynamic Severity in Pulmonary Arterial Hypertension.

Group 1 pulmonary hypertension (PH), i.e. pulmonary arterial hypertension (PAH), is associated with a metabolic shift favoring glycolysis in cells comprising the lung vasculature as well as skeletal muscle and right heart. We sought to determine whether this metabolic switch is also detectable in circulating platelets from PAH patients. We used Seahorse Extracellular Flux to measure bioenergetics in platelets isolated from group 1 PH (PAH), group 2 PH, patients with dyspnea and normal pulmonary artery pressures, and healthy controls. We show that platelets from group 1 PH patients exhibit enhanced basal glycolysis and lower glycolytic reserve compared with platelets from healthy controls but do not differ from platelets of group 2 PH or dyspnea patients without PH. Although unable to identify a glycolytic phenotype unique to platelets from PAH patients, we found that platelet glycolytic metabolism correlated with hemodynamic severity only in group 1 PH patients, supporting the known link between PAH pathology and altered glycolytic metabolism and extending this association to ex vivo platelets. Pulmonary artery pressure and pulmonary vascular resistance in patients with group 1 PH were directly associated with basal platelet glycolysis and inversely associated with maximal and reserve glycolysis, suggesting that PAH progression reduces the capacity for glycolysis even while demanding an increase in glycolytic metabolism. Platelets may therefore provide an easy to harvest, real-time window into the metabolic shift occurring in the lung vasculature and represent a useful surrogate for interrogating the glycolytic shift central to PAH pathology.

[1]  L. Que,et al.  Bioenergetic Differences in the Airway Epithelium of Lean Versus Obese Asthmatics Are Driven by Nitric Oxide and Reflected in Circulating Platelets. , 2019, Antioxidants & redox signaling.

[2]  M. Simon,et al.  Alterations in platelet bioenergetics in Group 2 PH-HFpEF patients , 2019, PloS one.

[3]  A. Newman,et al.  Platelet bioenergetics correlate with muscle energetics and are altered in older adults. , 2019, JCI insight.

[4]  Z. Jing,et al.  3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis , 2018, American journal of hypertension.

[5]  M. Humbert,et al.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.

[6]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[7]  A. Cuello,et al.  Platelets Bioenergetics Screening Reflects the Impact of Brain Aβ Plaque Accumulation in a Rat Model of Alzheimer , 2018, Neurochemical Research.

[8]  Richard B. Thompson,et al.  Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients , 2017, Science Translational Medicine.

[9]  Suzanne Craft,et al.  Blood-Based Bioenergetic Profiling Reflects Differences in Brain Bioenergetics and Metabolism , 2017, Oxidative medicine and cellular longevity.

[10]  J. Kline,et al.  Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism. , 2017, Thrombosis research.

[11]  J. Wang,et al.  High-intensity Interval Training Improves Mitochondrial Function and Suppresses Thrombin Generation in Platelets undergoing Hypoxic Stress , 2017, Scientific Reports.

[12]  F. Guyette,et al.  Biochemical signaling by remote ischemic conditioning of the arm versus thigh: Is one raise of the cuff enough? , 2017, Redox biology.

[13]  M. Gladwin,et al.  Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity. , 2017, JCI insight.

[14]  S. Pullamsetti,et al.  Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1 , 2016, Circulation.

[15]  S. Erzurum,et al.  Platelets from Asthmatic Individuals Show Less Reliance on Glycolysis , 2015, PloS one.

[16]  R. Dweik,et al.  O-Linked &bgr;-N-Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension , 2015, Circulation.

[17]  A. Droit,et al.  Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension , 2015, Journal of Molecular Medicine.

[18]  E. Michelakis,et al.  The Metabolic Theory of Pulmonary Arterial Hypertension , 2014, Circulation research.

[19]  E. Elmér,et al.  Cytokine and Nitric Oxide Levels in Patients with Sepsis – Temporal Evolvement and Relation to Platelet Mitochondrial Respiratory Function , 2014, PloS one.

[20]  S. Shiva,et al.  Platelet bioenergetic screen in sickle cell patients reveals mitochondrial complex V inhibition, which contributes to platelet activation. , 2014, Blood.

[21]  E. Michelakis,et al.  The metabolic basis of pulmonary arterial hypertension. , 2014, Cell metabolism.

[22]  Philip A. Kramer,et al.  Bioenergetics and the Oxidative Burst: Protocols for the Isolation and Evaluation of Human Leukocytes and Platelets , 2014, Journal of visualized experiments : JoVE.

[23]  Philip A. Kramer,et al.  A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: Implications for their use as bioenergetic biomarkers , 2014, Redox biology.

[24]  F. Caputo,et al.  Increased platelet oxidative metabolism, blood oxidative stress and neopterin levels after ultra-endurance exercise , 2014, Journal of sports sciences.

[25]  F. Martinez,et al.  Pulmonary hypertension due to left heart diseases. , 2013, Journal of the American College of Cardiology.

[26]  R. Dweik,et al.  Causes and circumstances of death in pulmonary arterial hypertension. , 2013, American journal of respiratory and critical care medicine.

[27]  James D. Thomas,et al.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. , 2013, Annals of the American Thoracic Society.

[28]  S. Archer,et al.  Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension , 2013, Pulmonary circulation.

[29]  A. Aponte,et al.  Platelet Mitochondrial Dysfunction is Evident in Type 2 Diabetes in Association with Modifications of Mitochondrial Anti-Oxidant Stress Proteins , 2011, Experimental and Clinical Endocrinology & Diabetes (Barth).

[30]  R. Dweik,et al.  Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[31]  S. Erzurum,et al.  Pulmonary artery endothelium resident endothelial colony-forming cells in pulmonary arterial hypertension , 2011, Pulmonary circulation.

[32]  J. Tamargo,et al.  Proteomic changes related to “bewildered” circulating platelets in the acute coronary syndrome , 2011, Proteomics.

[33]  S. Erzurum,et al.  Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. , 2010, Comprehensive Physiology.

[34]  M. D. de Leon,et al.  Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[35]  Qingmei Li,et al.  Platelets of type 2 diabetic patients are characterized by high ATP content and low mitochondrial membrane potential , 2009, Platelets.

[36]  S. Bombardieri,et al.  ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia. , 2008, Clinical biochemistry.

[37]  Kaihua Guo,et al.  Effects of ageing and Alzheimer’s disease on mitochondrial function of human platelets , 2008, Experimental Gerontology.

[38]  M. Maitland,et al.  Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. , 2008, American journal of physiology. Heart and circulatory physiology.

[39]  Nanette Freedman,et al.  Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  Jie Xu,et al.  Mitochondrial dysfunction in platelets and hippocampi of senescence-accelerated mice , 2007, Journal of bioenergetics and biomembranes.

[41]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[42]  S. Archer,et al.  An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.

[43]  J. Dyck,et al.  Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis , 2004, Circulation research.

[44]  M. Humbert,et al.  Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. , 2001, Clinics in chest medicine.

[45]  H. Baum,et al.  Decreased Pasteur effect in platelets of aged individuals , 2001, Mechanisms of Ageing and Development.

[46]  A. Kesy,et al.  Microplate reader--a convenient tool in studies of blood coagulation. , 1997, Thrombosis research.

[47]  V. S. Zhdanov,et al.  Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. , 1995, The American journal of pathology.

[48]  A H Schapira,et al.  Smoking and mitochondrial function: a model for environmental toxins. , 1993, The Quarterly journal of medicine.